Annual SG&A
$8.94 B
+$1.76 B+24.47%
31 December 2023
Summary:
Novo Nordisk A/S annual selling, general & administrative expenses is currently $8.94 billion, with the most recent change of +$1.76 billion (+24.47%) on 31 December 2023. During the last 3 years, it has risen by +$3.29 billion (+58.24%). NVO annual SG&A is now at all-time high.NVO Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.45 B
+$122.55 M+5.28%
30 September 2024
Summary:
Novo Nordisk A/S quarterly selling, general & administrative expenses is currently $2.45 billion, with the most recent change of +$122.55 million (+5.28%) on 30 September 2024. Over the past year, it has increased by +$389.76 million (+18.96%). NVO quarterly SG&A is now -9.04% below its all-time high of $2.69 billion, reached on 31 December 2023.NVO Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$64.22 B
+$5.23 B+8.87%
30 September 2024
Summary:
Novo Nordisk A/S TTM selling, general & administrative expenses is currently $64.22 billion, with the most recent change of +$5.23 billion (+8.87%) on 30 September 2024. Over the past year, it has increased by +$55.89 billion (+671.17%). NVO TTM SG&A is now at all-time high.NVO TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVO Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.5% | +19.0% | +671.2% |
| 3 y3 years | +58.2% | +52.1% | +919.8% |
| 5 y5 years | +69.5% | +87.2% | +1111.8% |
NVO Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +58.2% | -9.0% | +52.1% | at high | +56.8% |
| 5 y | 5 years | at high | +69.5% | -9.0% | +101.3% | at high | +103.8% |
| alltime | all time | at high | +9012.0% | -9.0% | +524.1% | at high | >+9999.0% |
Novo Nordisk A/S Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.45 B(+5.3%) | $9.56 B(+4.3%) |
| June 2024 | - | $2.32 B(+10.6%) | $9.17 B(+0.8%) |
| Mar 2024 | - | $2.10 B(-21.9%) | $9.10 B(+1.7%) |
| Dec 2023 | $8.94 B(+24.5%) | $2.69 B(+30.8%) | $8.94 B(+7.4%) |
| Sept 2023 | - | $2.06 B(-8.8%) | $8.33 B(+4.4%) |
| June 2023 | - | $2.25 B(+15.9%) | $7.98 B(+7.5%) |
| Mar 2023 | - | $1.94 B(-6.3%) | $7.42 B(+3.7%) |
| Dec 2022 | $7.19 B(+10.0%) | $2.07 B(+21.5%) | $7.16 B(+1.5%) |
| Sept 2022 | - | $1.71 B(+0.8%) | $7.06 B(+1.4%) |
| June 2022 | - | $1.69 B(+0.7%) | $6.96 B(+3.7%) |
| Mar 2022 | - | $1.68 B(-14.7%) | $6.71 B(+3.0%) |
| Dec 2021 | $6.53 B(+15.6%) | $1.97 B(+22.6%) | $6.51 B(+3.4%) |
| Sept 2021 | - | $1.61 B(+11.4%) | $6.30 B(+2.7%) |
| June 2021 | - | $1.44 B(-3.1%) | $6.13 B(+3.9%) |
| Mar 2021 | - | $1.49 B(-15.2%) | $5.90 B(+4.1%) |
| Dec 2020 | $5.65 B(+5.2%) | $1.76 B(+21.8%) | $5.67 B(+2.9%) |
| Sept 2020 | - | $1.44 B(+18.7%) | $5.51 B(+2.5%) |
| June 2020 | - | $1.21 B(-3.4%) | $5.38 B(-1.0%) |
| Mar 2020 | - | $1.26 B(-21.3%) | $5.43 B(+1.1%) |
| Dec 2019 | $5.37 B(+1.8%) | $1.60 B(+22.2%) | $5.37 B(+1.3%) |
| Sept 2019 | - | $1.31 B(+3.0%) | $5.30 B(+0.9%) |
| June 2019 | - | $1.27 B(+6.1%) | $5.25 B(-0.1%) |
| Mar 2019 | - | $1.20 B(-21.8%) | $5.25 B(-0.2%) |
| Dec 2018 | $5.28 B(+7.9%) | $1.53 B(+21.6%) | $5.26 B(+0.7%) |
| Sept 2018 | - | $1.26 B(-1.2%) | $5.23 B(+1.7%) |
| June 2018 | - | $1.27 B(+5.4%) | $5.14 B(+2.9%) |
| Mar 2018 | - | $1.21 B(-19.0%) | $4.99 B(+2.1%) |
| Dec 2017 | $4.89 B(+1.7%) | $1.49 B(+27.5%) | $4.89 B(+3.7%) |
| Sept 2017 | - | $1.17 B(+3.7%) | $4.71 B(-0.3%) |
| June 2017 | - | $1.13 B(+2.1%) | $4.73 B(-1.0%) |
| Mar 2017 | - | $1.10 B(-16.2%) | $4.77 B(-0.6%) |
| Dec 2016 | $4.81 B(+0.4%) | $1.32 B(+11.4%) | $4.80 B(-0.7%) |
| Sept 2016 | - | $1.18 B(+0.5%) | $4.84 B(+0.1%) |
| June 2016 | - | $1.18 B(+3.9%) | $4.83 B(-0.4%) |
| Mar 2016 | - | $1.13 B(-16.2%) | $4.85 B(+1.5%) |
| Dec 2015 | $4.79 B(+0.3%) | $1.35 B(+14.7%) | $4.78 B(+1.1%) |
| Sept 2015 | - | $1.18 B(-1.4%) | $4.73 B(-0.6%) |
| June 2015 | - | $1.19 B(+12.6%) | $4.76 B(+0.6%) |
| Mar 2015 | - | $1.06 B(-18.4%) | $4.73 B(-0.4%) |
| Dec 2014 | $4.77 B(-0.3%) | $1.30 B(+8.0%) | $4.75 B(-1.6%) |
| Sept 2014 | - | $1.20 B(+3.1%) | $4.83 B(+1.6%) |
| June 2014 | - | $1.17 B(+8.0%) | $4.76 B(+0.1%) |
| Mar 2014 | - | $1.08 B(-21.6%) | $4.75 B(-0.8%) |
| Dec 2013 | $4.79 B(+11.5%) | $1.38 B(+22.2%) | $4.79 B(+2.8%) |
| Sept 2013 | - | $1.13 B(-3.1%) | $4.66 B(+2.4%) |
| June 2013 | - | $1.16 B(+4.0%) | $4.55 B(+3.0%) |
| Mar 2013 | - | $1.12 B(-10.3%) | $4.42 B(+3.0%) |
| Dec 2012 | $4.29 B(+3.3%) | $1.25 B(+22.7%) | $4.29 B(+2.5%) |
| Sept 2012 | - | $1.02 B(-1.4%) | $4.19 B(-0.6%) |
| June 2012 | - | $1.03 B(+4.1%) | $4.21 B(-0.3%) |
| Mar 2012 | - | $992.02 M(-13.2%) | $4.22 B(+1.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $4.16 B(+9.8%) | $1.14 B(+9.3%) | $4.15 B(+2.9%) |
| Sept 2011 | - | $1.05 B(+0.1%) | $4.04 B(+2.6%) |
| June 2011 | - | $1.04 B(+13.5%) | $3.93 B(+5.3%) |
| Mar 2011 | - | $920.28 M(-10.2%) | $3.73 B(+1.3%) |
| Dec 2010 | $3.78 B(+11.2%) | $1.03 B(+8.7%) | $3.69 B(+2.2%) |
| Sept 2010 | - | $943.37 M(+11.6%) | $3.61 B(+3.9%) |
| June 2010 | - | $845.64 M(-3.1%) | $3.47 B(+0.9%) |
| Mar 2010 | - | $873.00 M(-7.7%) | $3.44 B(+2.9%) |
| Dec 2009 | $3.40 B(+9.2%) | $945.33 M(+17.1%) | $3.34 B(+2.8%) |
| Sept 2009 | - | $807.16 M(-0.9%) | $3.25 B(+1.7%) |
| June 2009 | - | $814.67 M(+4.8%) | $3.20 B(+0.5%) |
| Mar 2009 | - | $777.37 M(-9.1%) | $3.18 B(+2.3%) |
| Dec 2008 | $3.12 B(+13.8%) | $855.36 M(+13.7%) | $3.11 B(+3.1%) |
| Sept 2008 | - | $752.01 M(-5.7%) | $3.02 B(+2.9%) |
| June 2008 | - | $797.24 M(+12.9%) | $2.93 B(+4.5%) |
| Mar 2008 | - | $706.36 M(-7.2%) | $2.81 B(+2.3%) |
| Dec 2007 | $2.74 B(+16.2%) | $761.31 M(+14.0%) | $2.74 B(+2.8%) |
| Sept 2007 | - | $667.56 M(-0.5%) | $2.67 B(+4.0%) |
| June 2007 | - | $670.85 M(+4.2%) | $2.57 B(+3.9%) |
| Mar 2007 | - | $643.69 M(-6.4%) | $2.47 B(+8.1%) |
| Dec 2006 | $2.36 B(+19.7%) | $687.64 M(+21.8%) | $2.29 B(+6.1%) |
| Sept 2006 | - | $564.58 M(-1.8%) | $2.16 B(+4.0%) |
| June 2006 | - | $574.78 M(+25.1%) | $2.07 B(+5.8%) |
| Mar 2006 | - | $459.45 M(-17.5%) | $1.96 B(-0.1%) |
| Dec 2005 | $1.97 B(+14.4%) | $556.96 M(+15.5%) | $1.96 B(+1.9%) |
| Sept 2005 | - | $482.02 M(+4.3%) | $1.93 B(+3.5%) |
| June 2005 | - | $462.04 M(+0.0%) | $1.86 B(+3.9%) |
| Mar 2005 | - | $461.96 M(-11.2%) | $1.79 B(+3.6%) |
| Dec 2004 | $1.72 B(+16.9%) | $520.51 M(+24.7%) | $1.73 B(+43.1%) |
| Sept 2004 | - | $417.37 M(+6.5%) | $1.21 B(+52.8%) |
| June 2004 | - | $391.82 M(-1.9%) | $791.13 M(+98.1%) |
| Mar 2004 | - | $399.31 M | $399.31 M |
| Dec 2003 | $1.47 B(+22.8%) | - | - |
| Dec 2002 | $1.20 B(+10.1%) | - | - |
| Dec 2001 | $1.09 B(+10.7%) | - | - |
| Dec 2000 | $983.27 M(+7.8%) | - | - |
| Dec 1999 | $911.84 M(+13.8%) | - | - |
| Dec 1998 | $801.53 M(-12.2%) | - | - |
| Dec 1997 | $912.47 M(-31.2%) | - | - |
| Dec 1996 | $1.33 B(+8.0%) | - | - |
| Dec 1995 | $1.23 B(+14.7%) | - | - |
| Dec 1994 | $1.07 B(+73.4%) | - | - |
| Dec 1993 | $616.94 M(-40.9%) | - | - |
| Dec 1992 | $1.04 B(+119.3%) | - | - |
| Dec 1991 | $476.29 M(+11.6%) | - | - |
| Dec 1990 | $426.67 M(+33.5%) | - | - |
| Dec 1989 | $319.57 M(+29.8%) | - | - |
| Dec 1988 | $246.13 M(+10.3%) | - | - |
| Dec 1987 | $223.06 M(+103.6%) | - | - |
| Dec 1985 | $109.57 M(+11.6%) | - | - |
| Dec 1984 | $98.15 M | - | - |
FAQ
- What is Novo Nordisk A/S annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual SG&A year-on-year change?
- What is Novo Nordisk A/S quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly SG&A year-on-year change?
- What is Novo Nordisk A/S TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Novo Nordisk A/S?
- What is Novo Nordisk A/S TTM SG&A year-on-year change?
What is Novo Nordisk A/S annual selling, general & administrative expenses?
The current annual SG&A of NVO is $8.94 B
What is the all time high annual SG&A for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual selling, general & administrative expenses is $8.94 B
What is Novo Nordisk A/S annual SG&A year-on-year change?
Over the past year, NVO annual selling, general & administrative expenses has changed by +$1.76 B (+24.47%)
What is Novo Nordisk A/S quarterly selling, general & administrative expenses?
The current quarterly SG&A of NVO is $2.45 B
What is the all time high quarterly SG&A for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly selling, general & administrative expenses is $2.69 B
What is Novo Nordisk A/S quarterly SG&A year-on-year change?
Over the past year, NVO quarterly selling, general & administrative expenses has changed by +$389.76 M (+18.96%)
What is Novo Nordisk A/S TTM selling, general & administrative expenses?
The current TTM SG&A of NVO is $64.22 B
What is the all time high TTM SG&A for Novo Nordisk A/S?
Novo Nordisk A/S all-time high TTM selling, general & administrative expenses is $9.56 B
What is Novo Nordisk A/S TTM SG&A year-on-year change?
Over the past year, NVO TTM selling, general & administrative expenses has changed by +$55.89 B (+671.17%)